c-Met Modulators and Method of Use
US-2016185725-A1 · Jun 30, 2016 · US
Processes for preparing quinoline compounds and pharmaceutical compositions containing such compounds
US9717720B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9717720-B2 |
| Application number | US-201213984559-A |
| Country | US |
| Kind code | B2 |
| Filing date | Feb 10, 2012 |
| Priority date | Feb 10, 2011 |
| Publication date | Aug 1, 2017 |
| Grant date | Aug 1, 2017 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention is directed to processes for making and compositions containing quinolines such as formula I or pharmaceutically acceptable salts thereof wherein: X1 is H, Br, CI, or X2 is H, Br, CI, or n1 is 1-2; and n2 is 1-2.
First claim
Opening claim text (preview).
The invention claimed is: 1. A capsule pharmaceutical composition: Ingredient mg / unit dose total fill weight × 100 Compound IB with 50 ppm or less 10 of 6,7-dimethoxy-quinoline-4-ol (10 percent drug load formulation) Silicified Microcrystalline Cellulose 78.7 Croscarmellose sodium 5 Sodium starch glycolate 5 Fumed Silica 0.3 Stearic acid 1 Total 100 wherein compound IB has the structure: 2. The capsule pharmaceutical composition of claim 1 , wherein the formation of 6,7-dimethoxy-quinoline-4-ol in the pharmaceutical composition is minimized to 25 ppm or less from 0 to 6 months at 25° C. and 60 percent relative humidity. 3. The capsule pharmaceutical composition of claim 1 , wherein the formation of 6,7-dimethoxy-quinoline-4-ol in the pharmaceutical composition is minimized to 15 ppm or less from 0 to 6 months at 25° C. and 60 percent relative humidity. 4. The capsule pharmaceutical composition of claim 1 , wherein the formation of 6,7-dimethoxy-quinoline-4-ol in the pharmaceutical composition is minimized to 10 ppm or less from 0 to 6 months at 25° C. and 60 percent relative humidity. 5. A capsule pharmaceutical composition: Ingredient mg / unit dose total fill weight × 100 Compound IB with 50 ppm or less 50 of 6,7-dimethoxy-quinoline-4-ol (50 percent drug load formulation) Silicified Microcrystalline Cellulose 37.7 Croscarmellose sodium 5 Sodium starch glycolate 5 Fumed Silica 0.3 Stearic acid 2 Total 100 wherein compound IB has the structure: 6. The capsule pharmaceutical composition of claim 5 , wherein the formation of 6,7-dimethoxy-quinoline-4-ol in the pharmaceutical composition is minimized to 25 ppm or less from 0 to 6 months at 25° C. and 60 percent relative humidity. 7. The capsule pharmaceutical composition of claim 5 , wherein the formation of 6,7-dimethoxy-quinoline-4-ol in the pharmaceutical composition is minimized to 15 ppm or less from 0 to 6 months at 25° C. and 60 percent relative humidity. 8. The capsule pharmaceutical composition of claim 5 , wherein the formation of 6,7-dimethoxy-quinoline-4-ol in the pharmaceutical composition is minimized to 10 ppm or less from 0 to 6 months at 25° C. and 60 percent relative humidity. 9. The capsule pharmaceutical composition of claim 1 containing 25 mg of Compound IB. 10. The capsule pharmaceutical composition of claim 9 containing:
Assignees
Inventors
Classifications
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9717720B2 cover?
- The present invention is directed to processes for making and compositions containing quinolines such as formula I or pharmaceutically acceptable salts thereof wherein: X1 is H, Br, CI, or X2 is H, Br, CI, or n1 is 1-2; and n2 is 1-2.
- Who is the assignee on this patent?
- Wilson Jo Ann, Shah Khalid, Exelixis Inc
- What technology area does this patent fall under?
- Primary CPC classification A61K31/47. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Aug 01 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 9 related publications on this page (citations in our corpus or others sharing the same primary CPC).